Big in Japan
BigDNA granted patent for core vaccine technology in Japan
BigDNA has been granted a patent for its core bacteriophage vaccine platform in Japan, opening up this market for future vaccines using this technology, including vaccines against Influenza and Chlamydia. This follows the announcement last year of the patent granted for BigDNA’s Hepatitis B vaccine in Japan. The technology allows vaccines to be produced faster and more cost effectively than traditional methods.
On the 12 month anniversary of being awarded ‘Best New Life Sciences Company in Scotland’ by Scottish Enterprise at their Life Science Awards, BigDNA’s CEO Dr John March commented “This is an important commercial milestone for BigDNA and is great news for Scotland. Japan is an important region for us being the third largest market for vaccines and it is forecast that vaccine uptake in Japan is set to increase.”
This patent builds upon the links that BigDNA already has with Asia including a collaboration with the China Agricultural University in Beijing to develop a vaccine against Chlamydia in pigs. The Asia-pacific region is of great importance to BigDNA, being home to developed countries, such as Japan, Korea and Taiwan, and emerging economies, such as India, Malaysia, Thailand and China. Many in the latter groups are self-sufficient in funding national vaccination programs.